Blood Diseases

Harvard-led researchers offer potential new treatments for subtype of acute myeloid leukemia

December 23, 2013

An international team of researchers working in the Boston and Singapore labs of Harvard Stem Cell Institute (HSCI) Blood Program leader Daniel Tenen, MD, recently identified new candidates for the treatment of an acute myeloid leukemia (AML) subtype caused by mutations of CEBPA, a tumor suppressor. The findings were published in two separate studies:... Read more about Harvard-led researchers offer potential new treatments for subtype of acute myeloid leukemia

“Good” cells can go “bad” in a “bad neighborhood"

March 22, 2010

The general theory of cancer development holds that malignancies occur because of the presence of certain genetic elements within the affected cells.

But a new study by Harvard researchers at Massachusetts General Hospital (MGH) indicates that “good” cells can become cancerous because of exposure to a “bad” environment within the body — similarly to the way a “good boy” may turn to crime when exposed to the pressures of life in a crime-ridden neighborhood.

In their paper in today’s edition of the journal Nature, David T. Scadden and colleagues report that normal blood stem...

Read more about “Good” cells can go “bad” in a “bad neighborhood"

Cross-country collaboration leads to new model of leukemia development

July 31, 2013

Eight years ago, two former Stanford University postdoctoral fellows, one of them still in California and the other at the Harvard Stem Cell Institute (HSCI) in Cambridge, began exchanging theories about why patients with leukemia stop producing healthy blood cells. What was it, they asked, that caused bone marrow to stop producing normal blood-producing cells?... Read more about Cross-country collaboration leads to new model of leukemia development

HSCI publishes clinical trial results for therapeutic that amplifies blood stem cells

October 8, 2013

Starting with a discovery in zebrafish in 2007, Harvard Stem Cell Institute (HSCI) researchers have published initial results of a Phase Ib human clinical trial of a therapeutic that has the potential to improve the success of blood stem cell transplantation. This milestone, just nine short years after Harvard’s major commitment to stem cell biology, once again demonstrates the ability of HSCI investigators to carry a discovery from the lab bench to the clinic—fulfilling the promise on which the Institute was founded.... Read more about HSCI publishes clinical trial results for therapeutic that amplifies blood stem cells

Bone drug kills resistant cancer stem cells by making home unlivable

November 6, 2013

A bone drug already on the market for osteoporosis may kill chronic myelogenous leukemia (CML) stem cells thought to persist in the bone marrow after standard therapy, lowering the likelihood of disease recurrence, according to a new study in mice led by researchers at the Harvard Stem Cell Institute (HSCI), the Harvard Department of Stem Cell and Regenerative Biology, and Massachusetts General Hospital.... Read more about Bone drug kills resistant cancer stem cells by making home unlivable

Healthy stem cells generated from terminally ill patients with Pearson Marrow Pancreatic Syndrome

June 14, 2013

Using a difficult laboratory technique, HSCI physician-researchers have isolated genetically healthy stem cells from patients with Pearson Marrow Pancreas Syndrome (PS), a generally fatal infant blood disorder with less than a hundred reported cases worldwide. Children with PS experience a range of symptoms, most notably: anemia,...

Read more about Healthy stem cells generated from terminally ill patients with Pearson Marrow Pancreatic Syndrome

Pages